To Enrich or Not To Enrich: How Target Enrichment Can Advance Your Research The presentation will begin April 19, 2010 7:00 pm ET; 4:00 p.m. PT; 11:00pm GMT Sponsored by Agilent Technologies Brought to you by the Science/AAAS Business Office     Real Player   Real Media Video (56k/150k)   Windows Media Player   Windows Media Video (56k/150k)     Several methodologies for performing DNA target enrichment prior to next generation sequencing have been developed and utilized in a growing number of experimental studies. As the price of next gen sequencing continues to fall, the debate around whether to perform some type of selection is ongoing. A number of variables must be considered to make the best decision, including the number of samples, the amount of DNA available, the sequencing platform used, budget, reproducibility requirements, and the availability of automation. To clarify some of these issues, you are invited to view a discussion of the strategies for DNA target enrichment with our panel of distinguished thought leaders in a video webinar being presented online and live during the American Association for Cancer Research conference in Washington, D.C. During the broadcast, the presenters will: provide a general introduction to the target enrichment methods they use discuss how these technologies can be applied to the next gen sequencing workflow share data from studies that have benefited from their approaches   Speakers: Dr. Dale Hedges Hussman Institute for Human Genomics Miami, FL Dale J. Hedges, Ph.D. is an assistant professor of human genetics and serves as the Assistant Director of the Center for Genome Technology, part of the Hussman Institute of Human Genomics at the University of Miami. After receiving his bachelor’s degree in biology from Duke University, he studied human transposable elements in the laboratories of Dr. Mark Batzer (Louisiana State University, Baton Rouge) and Prescott Deininger (Tulane University, New Orleans). His primary research focuses on human transposable elements, including both their molecular biology and their relationship to human genetic diseases. In addition, he is also engaged in research examining the genetics of cleft lip and palate, multiple sclerosis, and autism. Through his role in the UM Center for Genome Technology, part of the Miller School of Medicine, Dr. Hedges is actively involved in the incorporation of novel genomic technologies into the process of searching for the genetic variation underlying human disease risk. Dr. Elaine Mardis Washington University in St. Louis St. Louis, MO Elaine Mardis holds a Ph.D. in biochemistry and chemistry and a B.S. in zoology from the University of Oklahoma. Prior to joining The Genome Center, she was a senior research scientist at BioRad Laboratories in Hercules, California. Dr. Mardis has worked at The Genome Center at Washington University School of Medicine since 1993, playing a pivotal role in the evaluation, optimization, and application of novel sequencing instrumentation, chemistry, and molecular biology toward improved genome sequencing. As co-director of the center and director of technology development, she helped develop methods and automation pipelines for sequencing the human genome. Dr. Mardis currently orchestrates the center’s efforts to explore next generation sequencing technologies and to transition them into production sequencing capabilities. She has research interests in the application of DNA sequencing to characterize cancer genomes, and in providing genomic resources that facilitate the use of nonhuman primates in human health research. Dr. Mardis serves on several NIH study sections and private scientific advisory boards. She is also a former director of Applied Biosystems. Dr. Jun S. Wei National Institutes of Health Bethesda, MD Dr. Jun Wei completed his undergraduate degree in biology at the University of Houston before doing his doctoral work at the Baylor College of Medicine, also in Houston. Following a postdoctoral fellowship in the National Human Genome Research Institute at the National Institutes of Health (NIH), Dr. Wei stayed on at NIH, first as a biologist and currently as a staff scientist, in the Pediatric Oncology Branch of the National Cancer Institute. Dr. Wei has been extensively published and is on three patent applications. He and his laboratory are currently focused on using next generation sequencing technologies to identify the causative genes for pediatric cancers.   Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Worldwide Commercial Editor for the journal Science and Program Director for Outreach.   ___________________________________________________________________________________________________   For the best experience we recommend you use Internet Explorer 6 (IE6) or higher on a Windows-based PC to view this webinar. Please ensure that you are using a computer with a stable internet connection and good bandwidth. To ensure the best possible performance of the webinar we recommend that you avoid using a dial-up connection. Note: please confirm the start time of the webinar in your time zone. A free time zone converter is available at www.timeanddate.com/worldclock/converter.html   Test Your System   Help   Download Real Player   Download Silverlight